These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1651 related articles for article (PubMed ID: 21219185)

  • 1. Natural innate and adaptive immunity to cancer.
    Vesely MD; Kershaw MH; Schreiber RD; Smyth MJ
    Annu Rev Immunol; 2011; 29():235-71. PubMed ID: 21219185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune surveillance of tumors.
    Swann JB; Smyth MJ
    J Clin Invest; 2007 May; 117(5):1137-46. PubMed ID: 17476343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TGF-beta: a master switch in tumor immunity.
    Gigante M; Gesualdo L; Ranieri E
    Curr Pharm Des; 2012; 18(27):4126-34. PubMed ID: 22630082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance.
    Chang RB; Beatty GL
    J Leukoc Biol; 2020 Jul; 108(1):363-376. PubMed ID: 32272502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The three Es of cancer immunoediting.
    Dunn GP; Old LJ; Schreiber RD
    Annu Rev Immunol; 2004; 22():329-60. PubMed ID: 15032581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy.
    Vesely MD; Schreiber RD
    Ann N Y Acad Sci; 2013 May; 1284(1):1-5. PubMed ID: 23651186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunobiology of cancer immunosurveillance and immunoediting.
    Dunn GP; Old LJ; Schreiber RD
    Immunity; 2004 Aug; 21(2):137-48. PubMed ID: 15308095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innate Immune Stimulation in Cancer Therapy.
    Düwell P; Heidegger S; Kobold S
    Hematol Oncol Clin North Am; 2019 Apr; 33(2):215-231. PubMed ID: 30832996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.
    Schreiber RD; Old LJ; Smyth MJ
    Science; 2011 Mar; 331(6024):1565-70. PubMed ID: 21436444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges.
    Kunimasa K; Goto T
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
    Cancel JC; Crozat K; Dalod M; Mattiuz R
    Front Immunol; 2019; 10():9. PubMed ID: 30809220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor immunoediting and immunosculpting pathways to cancer progression.
    Reiman JM; Kmieciak M; Manjili MH; Knutson KL
    Semin Cancer Biol; 2007 Aug; 17(4):275-87. PubMed ID: 17662614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immunoediting: from immunosurveillance to tumor escape.
    Dunn GP; Bruce AT; Ikeda H; Old LJ; Schreiber RD
    Nat Immunol; 2002 Nov; 3(11):991-8. PubMed ID: 12407406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity.
    Smyth MJ; Dunn GP; Schreiber RD
    Adv Immunol; 2006; 90():1-50. PubMed ID: 16730260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of tumorigenesis and tumor immunity in invertebrates and nonmammalian vertebrates.
    Robert J
    Dev Comp Immunol; 2010 Sep; 34(9):915-25. PubMed ID: 20553753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune system: a double-edged sword in cancer.
    Lakshmi Narendra B; Eshvendar Reddy K; Shantikumar S; Ramakrishna S
    Inflamm Res; 2013 Sep; 62(9):823-34. PubMed ID: 23868500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major fundamental factors hindering immune system in defense against tumor cells: The link between insufficiency of innate immune responses, metabolism, and neurotransmitters with effector immune cells disability.
    Bahrambeigi S; Sanajou D; Shafiei-Irannejad V
    Immunol Lett; 2019 Aug; 212():81-87. PubMed ID: 31260743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From mice to humans: developments in cancer immunoediting.
    Teng MW; Galon J; Fridman WH; Smyth MJ
    J Clin Invest; 2015 Sep; 125(9):3338-46. PubMed ID: 26241053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural immunity to cancer in humans.
    Bindea G; Mlecnik B; Fridman WH; Pagès F; Galon J
    Curr Opin Immunol; 2010 Apr; 22(2):215-22. PubMed ID: 20207124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer immunoediting from immune surveillance to immune escape.
    Kim R; Emi M; Tanabe K
    Immunology; 2007 May; 121(1):1-14. PubMed ID: 17386080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 83.